pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

It’s Over-ton; Thoughts on Isomorphic’s latest haul; and more

Nov 21, 2026·read at Endpoints ↗

Welcome back to another edition of Endpoints Weekly! All the tech outages this week can’t stop us from bringing you the latest in biopharma news. The biggest news this week came from Washington, where President ...

source

Reporting by Endpoints.

read at Endpoints ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 10h agoCapricor's Duchenne therapy is rejected again, as FDA cites significant issues with trialEndpoints
  • 16h agoMore lawmakers stake out stances on China biotech investmentEndpoints
  • 19h agoPharma layoffs continue in New Jersey; Bausch + Lomb drug misses endpointEndpoints
  • 19h agoKRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approachEndpoints
  • 20h agoMerck gets another Phase 3 win for sac-TMT, this time in gastric cancerEndpoints